Connect with us

Artificial Intelligence

AI slashes drug discovery timelines in China to 9 months

Published

on

AI drug discovery China

How fast can AI actually move a drug from idea to candidate? In China, the answer is under a year.

Insilico Medicine, a Hong Kong-listed biotech, has compressed what normally takes four and a half years into roughly 13 months — and in its fastest program, just nine. The company’s CEO Alex Zhavoronkov says that by blending generative AI with wet-lab work in China, his team can nominate a preclinical candidate before most traditional projects even finish target validation.

That timeline covers early discovery and candidate selection only. Clinical trials, manufacturing, and regulatory review still come after. But even shaving years off the front end is a big deal in an industry where speed can mean the difference between a blockbuster and a also-ran.

AI drug discovery China: The mechanics behind the speed

Insilico uses generative AI to hunt for biological targets, design candidate molecules, and decide which compounds deserve a trip to the lab. The company says its programs typically reach preclinical-candidate nomination within 12 to 18 months after researchers synthesize and test between 60 and 200 molecules. That’s a workflow where AI generates designs, humans review them, and experiments confirm what works.

Lab work hasn’t been eliminated — it’s just more targeted. The AI models flag the most promising compounds, so teams need to synthesize fewer molecules to find a winner. Insilico hasn’t published a head-to-head comparison of AI-assisted versus conventional programs, but the raw numbers are telling: since 2021, the company has generated 31 preclinical candidates. Thirteen of those have received investigational new drug (IND) clearances, meaning they can move toward human studies.

Where the work happens

AI model development and evaluation happen in Montreal and Abu Dhabi. The experimental validation and scale-up take place in Shanghai, where the company has automated parts of biological sampling and compound screening. It’s a split model that plays to each location’s strengths: cutting-edge AI research in the West, cost-effective lab capacity in China.

Zhavoronkov credits China’s research infrastructure, lower operating costs, and regulatory environment for shaving about two years off traditional candidate-development timelines. That’s not just a local advantage. International drugmakers already work with Chinese contract research organizations, clinical-trial centers, and biotech firms. A Pfizer executive recently told Reuters that clinical development in China can run three times faster and at about half the cost of equivalent work in Europe.

China also introduced a 30-working-day review pathway in 2025 for eligible Class I innovative-drug clinical-trial applications. Complex cases can go to a 60-working-day review. Compare that with the multi-month or multi-year waits common in Western markets, and the gap is stark.

The business reality: Western revenue, Chinese speed

Despite operating research facilities in China, more than 90% of Insilico’s revenue comes from Western pharmaceutical companies. The reason is simple: China’s national insurance system offers lower reimbursement rates for highly novel drugs, so licensing deals in the U.S. and Europe are far more lucrative. Zhavoronkov declined to disclose the company’s China revenue.

Geopolitical concerns also shape strategy. Insilico limits sales of most of its software within China, even as it plans to expand its Shanghai research operations. The company has struck R&D agreements with Eli Lilly and Japan’s Takeda, and announced a proposed strategic alliance with Taiwan-based Bora Pharmaceuticals that could exceed $2.5 billion if fully implemented.

Zhavoronkov put it bluntly: “We now compete with Chinese pharmaceutical companies on timelines, and with traditional biotechnology companies in the West on novelty.”

Rentosertib: Insilico’s first AI-born drug heads to Phase III

Insilico’s most advanced AI-designed drug is Rentosertib, an oral treatment for idiopathic pulmonary fibrosis (IPF) — a disease that progressively scars the lungs. The company used AI to identify the biological target and generate and optimize the molecule’s structure. Rentosertib already completed a smaller Phase IIa study. Now it’s moving to Phase III.

The Phase III trial, registered in July 2026, plans to enroll 320 participants across 47 centers in China. It will compare Rentosertib against a placebo over 52 weeks, with the primary endpoint measuring the annual rate of decline in forced vital capacity — a standard lung-function metric. Enrollment was expected to begin in August 2026, with primary completion estimated for October 2029.

Candidate nomination is still an early milestone. Drugs must clear preclinical testing, human trials, manufacturing validation, and regulatory review before reaching patients. Industry data haven’t yet proven that AI-designed drugs are more likely to succeed in later-stage trials. A 2024 analysis of AI-native biotech pipelines reported Phase I success rates between 80% and 90%, and a Phase II rate of about 40% — broadly in line with historical industry benchmarks. The researchers cautioned that the number of Phase II programs was too small to draw firm conclusions.

Insilico has produced 31 preclinical candidates and secured 13 IND clearances. Rentosertib is its first program to reach Phase III. None of its experimental medicines has received commercial approval.

AI and robotics are reshaping biotech jobs

AI and lab automation are also changing who Insilico hires — and who it might not need. Zhavoronkov estimated that about 40% of the company’s software-side workforce could eventually be automated or displaced. He stressed that this isn’t an announced staff reduction, but a forecast of how roles will evolve.

Insilico employs about 400 people. Laboratory scientists and software engineers are being retrained to manage AI evaluation systems, automated equipment, and robotics. The retraining focuses on AI benchmarks and robotic systems as the company automates more research and software functions.

For more on how AI is transforming industries, see our coverage of Bristol Myers Squibb buying Nvidia’s AI system for drug discovery and the broader AI and big data trends shaping enterprise technology.

Continue Reading

Artificial Intelligence

XDOF, three months out of stealth, is already closing in on a $1.2B Series B

Published

on

XDOF Series B

From stealth to unicorn talk in record time

Three months. That’s how long XDOF has been out in the open. And already, the robotics data startup is in late-stage conversations to raise a Series B at a valuation hovering around $1.2 billion, according to multiple sources familiar with the negotiations. The round would be led by 8VC.

Not bad for a company that didn’t even exist publicly until June.

XDOF was co-founded in 2024 by UC Berkeley researchers Philipp Wu (CEO) and Fred Shentu (CTO). Their origin story traces back to a research project called GELLO — a low-cost teleoperation system that lets a human operator control a robotic arm from a distance. The goal? Generate training data for robots. That work produced an influential paper in robotics and, eventually, a company.

The startup’s Series A, a $70 million round announced in June, drew participation from Thrive Capital, Andreessen Horowitz, Lux, and Spark Capital. At the time, XDOF wasn’t planning to raise again so soon. But the market had other ideas.

Why investors are knocking on XDOF’s door

The reason for the sudden interest? Growth. Real, measurable growth.

XDOF’s annualized revenue is approaching $50 million, sources say. That kind of traction, so soon after a Series A, tends to make venture capitalists sit up and take notice. It also tends to make them pick up the phone.

“They weren’t out raising,” one person familiar with the situation told TechCrunch. “The VCs came to them.”

Terms aren’t final, and the total capital being raised remains unclear. TechCrunch couldn’t confirm whether the $1.2 billion valuation includes the new funding or sits on top of it. Both XDOF and 8VC declined to comment.

The Scale AI for physical robots

XDOF’s pitch is straightforward: it builds the data pipelines, collection tools, and annotation systems that frontier AI labs and robotics companies would rather not build themselves. Think of it as an outsourced data-supply chain for the robotics industry.

Investors describe XDOF as the Scale AI or Mercor of physical robotics — a nod to the data-labeling giants that powered the AI boom. The comparison makes sense. Large language models trained on the entire internet. Physical robots? They don’t have that luxury. There’s no massive, ready-made dataset of real-world robot interactions sitting online. That scarcity makes data collection the critical bottleneck on the road to general-purpose machines.

Wu felt that bottleneck firsthand as a PhD student. His research on how robots learn from large datasets kept hitting the same wall: “large-scale data to work with” simply didn’t exist, he told TechCrunch in June.

Building the ABC dataset

XDOF is tackling that problem head-on. The startup is partnering with UC Berkeley’s AI Research lab to release what it believes is the largest collection of high-quality robot training data ever assembled. The dataset is called ABC.

Collecting that data requires a hybrid approach. XDOF combines remote robot teleoperation with human collectors who wear sensors to record everyday tasks. Think folding clothes. Flattening boxes. The mundane, physical chores that robots still struggle to master.

The company plans to hire and train teams of data collectors around the world. Two main roles are emerging:

  • Teleoperators who steer robots remotely to demonstrate tasks
  • Egocentric operators who wear body sensors to capture natural movement data

Early traction and the competitive landscape

XDOF has already signed up 20 customers, including several frontier AI labs, according to previous statements to TechCrunch. That customer base, combined with the revenue trajectory, helps explain the valuation chatter.

But XDOF isn’t alone in this niche. Other startups chasing real-world data for robot training include Mecka AI. And the human-data platforms that started with LLMs — like Scale AI and Micro1 — are expanding beyond text and images into physical domains.

The race to build the data infrastructure for physical AI is heating up. Whoever wins it will effectively control the fuel supply for the next generation of robots. That’s a position worth paying up for.

Whether the $1.2 billion valuation holds remains to be seen. Deals at this stage can shift. But the fact that XDOF is even in this conversation — three months after emerging from stealth — says something about the demand for what it’s building.

For more on how data is shaping the future of AI, check out AI data labeling trends and robotics funding rounds in 2024.

Continue Reading

Artificial Intelligence

New York City Pulls AI From Younger Classrooms—Here’s Why It Matters

Published

on

NYC AI ban

New York City Just Hit Pause on AI in Classrooms

New York City Public Schools is drawing a hard line: no generative AI for students from 2-K through eighth grade during the 2026-2027 school year. That’s over half a million kids walking into classrooms next week without access to AI-powered tools.

The district says it will remove software with student-facing AI features and block AI companion chatbots. High schoolers? They’re exempt. This isn’t a blanket ban—it’s a targeted move to decide when kids should actually start using the technology.

Mayor Zohran Mamdani put it bluntly: “The tech industry wants us to believe that AI-powered early education is not only inevitable, but necessary. We do not see it that way.”

Why NYC Is Worried About AI for Younger Students

The fear isn’t just that a kid will ask ChatGPT to write an essay. City officials want younger students to build core skills—critical thinking, creativity, communication—without leaning on AI as a crutch. They’re also pushing for stronger human connections in classrooms, not another screen.

Schools Chancellor Kamar Samuels said the city refuses to assume that innovation automatically equals more technology in front of students. It’s a deliberate slowdown, and it follows last year’s bell-to-bell cellphone ban that already limits device use during school hours.

What Happens When Kids Reach High School?

AI doesn’t vanish once students hit ninth grade. Instead, the district plans to roll out AI literacy classes twice a year. The goal? Teach teenagers how to think critically about the technology before they become dependent on it.

That’s a different approach from just saying no. It’s about timing—letting younger minds develop without AI, then giving older students the tools to question it.

The National Battle Over AI in Education

NYC’s decision sits at the center of a much bigger fight. The White House has pushed educators to embrace AI responsibly. Some teachers already use it to craft lesson plans, give feedback, or break down tough subjects. But not everyone’s on board.

The Department of Health and Human Services recently gathered childhood experts to talk about excessive screen time. Officials have also called for tougher safeguards around social media and AI. The message? Kids are spending too much time in front of screens, and AI might make it worse.

A Bold Experiment With Zero AI

Here’s what makes NYC’s move so interesting: instead of asking how much AI younger students should use, the largest school district in the country is starting with none. For one academic year, they’re testing whether classrooms are better off with AI kept outside the door.

That’s a radical stance, and it’s not without critics. Some educators argue AI can personalize learning or help struggling students catch up. But NYC is betting that a year without AI will reveal what kids actually need—not what tech companies think they need.

What This Means for Parents and Teachers

If you’re a parent in NYC, expect changes. AI-based apps may disappear from your child’s school day. Teachers will need to plan lessons without generative AI tools. And students in grades 2-K through 8 will rely more on traditional methods—paper, pencils, and human interaction.

For teachers elsewhere, this could be a signal. NYC is the biggest district to take this stance, and its findings could shape policies nationwide. The next year will be watched closely by educators, policymakers, and tech giants alike.

What Happens Next?

The district will spend the year studying how generative AI affects students before deciding what comes next. That research could lead to a permanent ban, a partial rollout, or something entirely different.

For now, NYC is making a statement: childhood shouldn’t be an AI beta test. Whether that’s the right call or a step backward, we’ll know more in 2027. Until then, the debate over AI in schools just got a lot more interesting.

If you’re curious about how AI is shaping other areas, check out our take on AI in education trends or classroom technology policies.

Continue Reading

Artificial Intelligence

Meta’s Muse Spark 1.3 takes on GPT-5.6 and Claude — but can it really win?

Published

on

Muse Spark 1.3

Meta just fired a serious shot in the AI arms race

The company quietly unleashed Muse Spark 1.3, its most advanced AI model to date, and it’s aiming straight at the top dogs. Developers can already access and pay for the update, which Meta says represents a massive leap forward in performance.

It won’t stay confined to the developer sandbox for long. Over the coming weeks, the model will roll out across Instagram, Facebook, and the Meta AI assistant — putting it in front of billions of everyday users.

What makes Muse Spark 1.3 actually different?

Meta’s Chief AI Officer, Alexandr Wang, didn’t mince words. He called this “the biggest jump so far on model performance,” pointing to serious gains in two areas: coding and agentic tasks — the kind where the AI acts on your behalf rather than just answering questions.

But here’s the catch. Wang told Bloomberg that Muse Spark 1.3 is competitive with Anthropic’s Claude Fable 5.1 and even beats OpenAI’s GPT-5.6 Sol at coding. That’s a bold claim, especially with OpenAI’s upcoming Astra model lurking in the wings.

Take those comparisons with a grain of salt, though. Benchmarks can be gamed, and a model that crushes one test might stumble on a totally different task. Real-world performance is what actually matters.

Efficiency gains under the hood

Wang broke down a few upgrades that set Muse Spark 1.3 apart:

  • 25% fewer tokens needed to complete the same job — meaning lower costs and faster responses
  • Multi-workflow handling — it can juggle several tasks at once instead of forcing separate sessions
  • Better context retention across long, complicated instructions
  • Self-awareness of limits — the model now pauses to ask for clarification before taking any irreversible action

That last point is quietly important. AI that knows when it doesn’t know is a big step toward trustworthiness, especially for agentic use cases.

Pricing stays flat, adoption explodes

Here’s something developers will appreciate: Meta isn’t raising prices. Muse Spark 1.3 costs the same as its predecessor, Muse Spark 1.2. That’s a smart move when rivals are hiking rates.

Wang told Bloomberg that adoption on Meta’s developer platform has been strong — some users are burning through trillions of tokens every week. Those numbers suggest real usage, not just hype.

What about open-source fans? Meta hasn’t decided whether it will release the model’s weights — the blueprint that lets outside developers build on top of it. The older Muse Spark 1.2 weights are still headed for release, but the new model’s future remains unclear.

The bigger picture: Meta’s spending spree continues

Meta is still pouring billions into AI infrastructure, and Muse Spark 1.3 is the clearest signal yet that the company believes it’s closing the gap with OpenAI and Anthropic. Whether that’s true or just corporate bravado will play out in the benchmarks and real-world deployments over the coming months.

For now, the model is available to developers, and the app rollout is imminent. If you’re building on Meta AI tools, this update is worth a serious look. And if you’re just a curious user, you’ll likely meet Muse Spark 1.3 in your Instagram feed sooner than you think.

One thing’s certain: the AI race just got a lot more interesting.

Continue Reading

Trending